Utah Medical Products (UTMD) AI Stock Analysis

• Market Cap: $182.91M
• Dividend Yield: 2.16%
• Average Volume (3M): 15.00K
• Price to Earnings (P/E): 15.1
• Beta (1Y): 0.56
• Revenue Growth: -16.64%
• EPS Growth: N/A
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.94
• Shares Outstanding: 3,248,210
• 10 Day Avg. Volume: 12,260
• 30 Day Avg. Volume: 14,999
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.56
• Enterprise Value/Revenue: 2.62
• Enterprise Value/Gross Profit: 4.59
• Enterprise Value/Ebitda: 6.70
• 1Y Price Target: $62.00
• Price Target Upside: 10.10% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 73 Outperform
• Price Target: $62.00 ▲(10.10% Upside)

Utah Medical Products has a strong financial foundation with solid profitability and minimal leverage, which is the most significant factor supporting its stock score. The technical analysis indicates a bearish trend, which slightly dampens the overall score. The valuation is fair, providing a balanced view of the stock's potential. The absence of recent earnings call data and notable corporate events means these factors do not influence the score.

Utah Medical Products Business Overview & Revenue Model

Company Description

Utah Medical Products, Inc. (UTMD) is a medical device company that specializes in the development, manufacture, and marketing of proprietary medical products primarily for use in the hospital and home healthcare settings. The company operates in several sectors, including obstetrics, urology, and surgery, and offers a range of core products such as disposable surgical devices, urodynamic equipment, and neonatal care products designed to improve patient outcomes and enhance healthcare efficiency.

How the Company Makes Money

UTMD generates revenue primarily through the sale of its medical devices, which are distributed to hospitals, clinics, and healthcare providers both domestically and internationally. The company's revenue model is based on the direct sales of its proprietary products, which are often sold under long-term contracts or as part of bulk orders. Key revenue streams include sales from its obstetric and urological product lines, as well as ongoing revenue from consumables and accessories related to these devices. Additionally, UTMD benefits from strategic partnerships with medical distributors and healthcare organizations, which enhance its market reach and contribute to consistent sales growth. The company also invests in research and development to innovate and expand its product offerings, thereby driving future revenue potential.

Utah Medical Products Financial Statement Overview

Summary

Utah Medical Products displays a robust financial position with strong profitability, minimal leverage, and efficient cash flow management. Despite a decline in revenue and operating cash flow in the TTM, the company maintains solid margins and a healthy balance sheet, supporting its stability and growth potential in the medical instruments sector.

Income Statement

The income statement reveals a declining revenue trend over the years, with a revenue decrease from $52.28M in 2022 to $39.27M in the TTM. However, the company maintains strong profitability with a consistent gross profit margin and a solid net profit margin of approximately 33% in the TTM. The EBIT and EBITDA margins are robust, reflecting efficient cost management.

Balance Sheet

The balance sheet is strong, with a very low debt-to-equity ratio indicating minimal leverage, enhancing financial stability. The equity ratio is high, showcasing a strong capital structure with stockholders' equity making up a significant portion of total assets. However, a slight decrease in stockholders' equity is noted in the TTM.

Cash Flow

The cash flow statement shows healthy free cash flow generation with minimal capital expenditures. The operating cash flow to net income ratio is strong, indicating efficient cash conversion. However, there is a decline in operating cash flow from $21.23M in 2022 to $14.02M in the TTM, which may need attention.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	40.90M	50.22M	52.28M	49.05M	42.18M
Gross Profit	24.14M	30.04M	32.20M	30.92M	25.55M
EBITDA	16.44M	24.75M	26.87M	26.16M	20.92M
Net Income	13.87M	16.64M	16.47M	14.79M	10.80M
Balance Sheet
Total Assets	122.54M	135.46M	123.87M	115.56M	111.75M
Cash, Cash Equivalents and Short-Term Investments	82.98M	92.87M	75.05M	60.97M	51.59M
Total Debt	282.00K	295.00K	341.00K	396.00K	335.00K
Total Liabilities	5.11M	7.14M	9.62M	8.42M	8.92M
Stockholders Equity	117.43M	128.31M	114.25M	107.14M	102.82M
Cash Flow
Free Cash Flow	14.60M	21.64M	20.33M	20.65M	19.28M
Operating Cash Flow	14.83M	22.28M	21.15M	21.20M	20.14M
Investing Cash Flow	-208.00K	-639.00K	-818.00K	-552.00K	-860.00K
Financing Cash Flow	-23.84M	-4.17M	-5.48M	-10.90M	-10.73M

Utah Medical Products Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 56.31
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Neutral. The current price of 56.31 is below the 20-day moving average (MA) of 56.48, above the 50-day MA of 56.27, and below the 200-day MA of 58.33, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 49.09 is Neutral, neither overbought nor oversold. The STOCH value of 39.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for UTMD.

Utah Medical Products Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PDEX	75 Outperform	$155.71M	17.06	28.29%	―	29.65%	131.78%
UTMD	73 Outperform	$182.91M	15.06	10.39%	2.16%	-16.64%	―
INFU	73 Outperform	$180.36M	37.23	9.39%	―	8.13%	1293.06%
STXS	64 Neutral	$225.63M	―	-198.62%	―	33.94%	-6.91%
OSUR	54 Neutral	$204.05M	25.27	-12.65%	―	-49.35%	-285.61%
Sector *	51 Neutral	$7.35B	-0.20	-44.62%	2.33%	29.35%	-1.02%
SMTI	44 Neutral	$220.42M	―	-28.58%	―	34.65%	-128.56%